| Compound Information | SONAR Target prediction | | Name: | EPIANDROSTANEDIOL | | Unique Identifier: | SPE00107093 | | MolClass: | Checkout models in ver1.5 and ver1.0 | | Molecular Formula: | C19H32O2 | | Molecular Weight: | 261.21 g/mol | | X log p: | -0.0960000000000001 (online calculus) | | Lipinksi Failures | 0 | | TPSA | 0 | | Hydrogen Bond Donor Count: | 0 | | Hydrogen Bond Acceptors Count: | 2 | | Rotatable Bond Count: | 0 | | Canonical Smiles: | CC12CCC3C(CCC4CC(O)CCC43C)C1CCC2O | | Source: | ex numerous mammalian tissues | | Therapeutics: | regulation of puberty in females | | Generic_name: | 5-ALPHA-ANDROSTANE-3-BETA,17BETA-DIOL | | Chemical_iupac_name: | 5-ALPHA-ANDROSTANE-3-BETA,17BETA-DIOL | | Drug_type: | Experimental | | Drugbank_id: | EXPT00530 | | Logp: | 3.73 | | Drug_category: | Sex Hormone-Binding Globulin inhibitor | | Organisms_affected: | -1 |
| Species: |
4932 |
| Condition: |
YPT6 |
| Replicates: |
2 |
| Raw OD Value: r im |
0.4058±0.0258801 |
| Normalized OD Score: sc h |
0.6111±0.0396115 |
| Z-Score: |
-13.0383±0.687834 |
| p-Value: |
1.93877e-36 |
| Z-Factor: |
0.544035 |
| Fitness Defect: |
82.231 |
| Bioactivity Statement: |
Active |
| Experimental Conditions | | | Library: | Spectrum | | Plate Number and Position: | 2|G7 | | Drug Concentration: | 50.00 nM | | OD Absorbance: | 600 nm | | Robot Temperature: | 21.70 Celcius | | Date: | 2006-02-22 YYYY-MM-DD | | Plate CH Control (+): | 0.040999999999999995±0.00084 | | Plate DMSO Control (-): | 0.64005±0.01231 | | Plate Z-Factor: | 0.9372 |
|  png
ps
pdf |
| 15939349 |
[(1S,5S,7S)-7-bicyclo[3.2.0]heptyl]methanol |
| 15939714 |
octadecan-1-olate |
| 15939974 |
(2R,4S)-2,4,6-trimethylheptan-1-ol |
| 15940068 |
(1R,3aS,7aS)-2,3,3a,4,5,6,7,7a-octahydro-1H-inden-1-ol |
| 15966281 |
n/a |
| 15972052 |
magnesium (1S,4R,6R)-6-deuterio-1,4,7,7-tetramethyl-bicyclo[2.2.1]heptan-6-olate bromide |
| internal high similarity DBLink | Rows returned: 38 | 1 2 3 4 5 6 7 Next >> |
| active | Cluster 12674 | Additional Members: 6 | Rows returned: 4 | |
|
